Telangiectasis
Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders.
Subtype terms (4)
More specific conditions that are subtypes of Telangiectasis in the MeSH hierarchy.
- Ataxia Telangiectasia
31 drugs (28 approved, 3 experimental)
- CREST Syndrome
2 drugs (1 approved, 1 experimental)
- Retinal Telangiectasis
6 drugs (4 approved, 2 experimental)
- Telangiectasia, Hereditary Hemorrhagic
19 drugs (15 approved, 4 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (2)
Phase 3 trials (1)
Phase 2 trials (2)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (9)
Organization Involved with Phase 3 Indications (18)
- Baxalta
- Erydel
- Pharmacia
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- Augusta University
- University of London
- Hospital Italiano de Buenos Aires
- University of Bordeaux
- Yale University
- Asociación para Evitar la Ceguera en México
- Saarland University
- Adolphe Rothschild Ophtalmologic Foundation
- University of Lyon
- Sao Rafael Hospital, Monte Tabor Foudation
- University of Burgundy
- Cure HHT
- Association Maladie de Rendu-Osler
Organization Involved with Phase 2 Indications (42)
- Schering-Plough
- Genentech
- Alcon
- Novartis
- GlaxoSmithKline
- Neurotech Pharmaceuticals
- The EMMES Corporation
- Unity Health Toronto
- University of Pittsburgh
- Barrow Neurological Institute
- Harvard University
- Duke University
- Manhattan Eye, Ear & Throat Hospital
- Radboud University
- RTI International
- University of Pavia
- University of Toronto
- University of Bonn
- Mayo Clinic
- University of British Columbia
- University of California, San Diego
- University of Vienna
- Feinstein Institute for Medical Research
- Department of Defense
- University of Queensland
- St. Antonius Hospital, Nieuwegein
- Technion University
- University of North Carolina at Chapel Hill
- Eye Center of Northern Colorado
- University of Massachusetts
- +12 more
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (8)